Bionomics Limited
NASDAQ:BNOX
0.6418 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.099 | 0.047 | 0.344 | 0.173 | 0.09 | 0.042 | 4.064 | 0.123 | 0.242 | 0.467 | 0.096 | 1.196 | 1.133 |
| Cost of Revenue
| 5.268 | 2.484 | 5.897 | 2.959 | 7.325 | 3.441 | 6.244 | 5.054 | 2.781 | 1.583 | 0 | 2.681 | 0 |
| Gross Profit
| -5.169 | -2.438 | -5.552 | -2.787 | -7.235 | -3.399 | -2.18 | -4.931 | -2.539 | -1.117 | 0.096 | -1.485 | 1.133 |
| Gross Profit Ratio
| -52.25 | -52.25 | -16.13 | -16.13 | -80.036 | -80.036 | -0.536 | -40.067 | -10.482 | -2.394 | 1 | -1.241 | 1 |
| Reseach & Development Expenses
| 5.268 | 2.484 | 5.897 | 2.959 | 7.325 | 3.441 | 6.244 | 5.054 | 2.781 | 1.583 | 1.317 | 2.681 | 0 |
| General & Administrative Expenses
| 4.12 | 1.943 | 3.034 | 1.523 | 2.778 | 1.305 | 1.907 | 3.369 | 1.71 | 1.614 | 0 | 1.423 | 0 |
| Selling & Marketing Expenses
| 0.076 | 0.036 | 0.073 | 0.037 | 0.076 | 0.036 | 0.066 | 0.121 | 0.446 | 0.522 | 0 | 0.387 | 0 |
| SG&A
| 4.196 | 1.979 | 3.107 | 1.559 | 2.854 | 1.341 | 1.973 | 3.49 | 2.156 | 2.136 | 2.25 | 1.81 | 3.003 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 5.517 | 2.602 | 5.117 | 2.568 | 3.993 | 1.876 | 3.895 | 4.613 | 3.335 | 1.402 | 3.568 | 2.658 | 3.003 |
| Operating Income
| -9.366 | -4.417 | -8.659 | -4.346 | -10.089 | -4.739 | -4.153 | -8.416 | -4.619 | -3.174 | -3.471 | -3.295 | -1.87 |
| Operating Income Ratio
| -94.663 | -94.663 | -25.155 | -25.155 | -111.607 | -111.608 | -1.022 | -68.389 | -19.069 | -6.804 | -36.067 | -2.754 | -1.65 |
| Total Other Income Expenses Net
| -1.182 | -0.557 | -1.826 | -0.916 | -1.016 | -0.477 | -1.925 | -1.138 | -1.962 | 3.09 | 3.661 | -1.34 | 2.633 |
| Income Before Tax
| -10.547 | -4.974 | -10.485 | -5.262 | -11.105 | -5.216 | -6.077 | -9.554 | -6.58 | -0.084 | 0.19 | -4.635 | 0.763 |
| Income Before Tax Ratio
| -106.608 | -106.608 | -30.459 | -30.459 | -122.847 | -122.847 | -1.496 | -77.634 | -27.168 | -0.18 | 1.972 | -3.874 | 0.673 |
| Income Tax Expense
| 0.073 | 0.034 | 0.069 | 0.034 | 0.071 | 0.033 | 0.067 | 0.069 | 0.068 | 0.074 | -0.072 | 0.069 | -0.309 |
| Net Income
| -10.475 | -4.94 | -10.416 | -5.228 | -11.034 | -5.183 | -6.011 | -9.484 | -6.512 | -0.01 | -0.465 | -4.566 | 1.072 |
| Net Income Ratio
| -105.873 | -105.873 | -30.26 | -30.26 | -122.064 | -122.065 | -1.479 | -77.073 | -26.886 | -0.021 | -4.831 | -3.816 | 0.946 |
| EPS
| -1.1 | -0.52 | -1.18 | -0.59 | -1.47 | -0.69 | -1.02 | -1.7 | -1.42 | -0.002 | -0.13 | -1.47 | 0.31 |
| EPS Diluted
| -1.1 | -0.52 | -1.18 | -0.59 | -1.47 | -0.69 | -0.64 | -1.7 | -1.42 | -0.002 | -0.13 | -1.47 | 0.31 |
| EBITDA
| -9.03 | -4.258 | -8.307 | -4.191 | -9.774 | -4.591 | -3.839 | -8.075 | -4.448 | -2.627 | -4.198 | -2.792 | 1.144 |
| EBITDA Ratio
| -91.266 | -91.266 | -24.133 | -24.261 | -108.127 | -108.128 | -0.945 | -65.62 | -18.363 | -5.631 | -43.614 | -2.334 | 1.01 |